177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

1. Morris, M.J.
2. Castellano, D.
3. Herrmann, K.
4. de Bono, J.S.
5. Shore, N.D.
6. Chi, K.N.
7. Crosby, M.
8. Piulats, J.M.
9. Fléchon, A.
10. Wei, X.X.
11. Mahammedi, H.
12. Roubaud, G.
13. Študentová, H.
14. Nagarajah, J.
15. Mellado, B.
16. Montesa-Pino, Á.
17. Kpamegan, E.
18. Ghebremariam, S.
19. Kreisl, T.N.
20. Wilke, C.
21. Lehnhoff, K.
22. Sartor, O.
23. Fizazi, K.